Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,585 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03086954 | Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma(EECPL) | unknown | Phase 1 | 24 | Sinobioway Cell Therapy Co., Ltd.INDUSTRY | 1 | Mar 22, 2017 | clinicaltrials |
| NCT03085966 | Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC | unknown | Phase 1 / Phase 2 | 30 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 21, 2017 |
| NCT03084380 | Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 1 / Phase 2 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT02685670 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma(MatchCART) | unknown | Phase 1 / Phase 2 | 20 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT02031731 | The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 30 | Hoffmann-La RocheINDUSTRY | 1 | Mar 14, 2017 | clinicaltrials |
| NCT02441972 | Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics | unknown | Phase 1 | 200 | Wuxi No. 4 People's HospitalOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT02721407 | Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients(MendCART) | unknown | Phase 1 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT02695550 | Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer | unknown | Phase 1 | 40 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Mar 9, 2017 | clinicaltrials |
| NCT03026881 | A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | unknown | Phase 1 | 24 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 7, 2017 | clinicaltrials |
| NCT02836171 | Effect of Itraconazole on the Pharmacokinetics of Apatinib | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 27, 2017 | clinicaltrials |
| NCT02836821 | Effect of Rifampicin on the Pharmacokinetics of Apatinib | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 27, 2017 | clinicaltrials |
| NCT03062982 | Food-Effect and Metabolism Study in Healthy Subjects | completed | Phase 1 | 16 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT03050411 | Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer | unknown | Phase 1 | 30 | Peking University Third HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 200 | Xiaoyi HuangOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT02762474 | Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer | unknown | Phase 1 / Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT03030001 | PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | unknown | Phase 1 / Phase 2 | 40 | Ningbo Cancer HospitalINDUSTRY | 1 | Jan 24, 2017 | clinicaltrials |
| NCT02650375 | Study of Metatinib Tromethamine Tablet | unknown | Phase 1 | 24 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2017 | clinicaltrials |
| NCT03018093 | A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL | unknown | Phase 1 | 20 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Jan 20, 2017 | clinicaltrials |
| NCT02429622 | Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma | completed | Phase 1 / Phase 2 | 80 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 18, 2017 | clinicaltrials |
| NCT02720666 | K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's Tolerability | completed | Phase 1 | 12 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT03013712 | A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer(CARTEPC) | unknown | Phase 1 / Phase 2 | 60 | First Affiliated Hospital of Chengdu Medical CollegeOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT02993913 | Safety, Tolerability and Pharmacokinetics of Simmiparib in Patients With Malignant Advanced Solid Tumor | unknown | Phase 1 | 50 | Shanghai Acebright Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 5, 2017 | clinicaltrials |
| NCT01832298 | Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor | completed | Phase 1 | 39 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Dec 20, 2016 | clinicaltrials |
| NCT02236884 | The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer | completed | Phase 1 / Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Dec 19, 2016 | clinicaltrials |
| NCT02987244 | Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT02617134 | CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02892695 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02944162 | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02983942 | Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 50 | Beijing Tiantan HospitalOTHER | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02980315 | A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application | unknown | Phase 1 / Phase 2 | 20 | The Second Hospital of Nanjing Medical UniversityOTHER | 1 | Dec 2, 2016 | clinicaltrials |
| NCT02977364 | A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours | unknown | Phase 1 | 50 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 30, 2016 | clinicaltrials |
| NCT02274337 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02968472 | A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia | unknown | Phase 1 | 30 | The First People's Hospital of YunnanOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02965157 | Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma | unknown | Phase 1 / Phase 2 | 15 | Beijing Biohealthcare Biotechnology Co.,LtdINDUSTRY | 1 | Nov 16, 2016 | clinicaltrials |
| NCT02959151 | A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy | unknown | Phase 1 / Phase 2 | 20 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Nov 8, 2016 | clinicaltrials |
| NCT02819583 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Oct 25, 2016 | clinicaltrials |
| NCT02939378 | Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study(KGDinrGBM) | unknown | Phase 1 / Phase 2 | 60 | Song LinOTHER | 1 | Oct 20, 2016 | clinicaltrials |
| NCT02937844 | Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme | unknown | Phase 1 | 20 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT02810223 | Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Beijing Sanwater Biological Technology Co., Ltd.INDUSTRY | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02933775 | CD19-redirected Autologous Cells (CAR-CD19 T Cells) | unknown | Phase 1 | 45 | RenJi HospitalOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02903810 | Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy | unknown | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Oct 12, 2016 | clinicaltrials |
| NCT02930967 | Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors | unknown | Phase 1 | 20 | China Meitan General HospitalOTHER | 1 | Oct 12, 2016 | clinicaltrials |
| NCT02930993 | Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors | unknown | Phase 1 | 20 | China Meitan General HospitalOTHER | 1 | Oct 12, 2016 | clinicaltrials |
| NCT02873390 | PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | Ningbo Cancer HospitalINDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02873416 | Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer | unknown | Phase 1 / Phase 2 | 40 | Ningbo Cancer HospitalINDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02873442 | Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 40 | Ningbo Cancer HospitalINDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02873520 | Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 40 | Ningbo Cancer HospitalINDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials